{"favorite_id": 10437, "calc_type": "calculator", "dosing": false, "full_title_en": "Model for End-Stage Liver Disease (Combined MELD)", "short_title_en": "Combined MELD", "medium_description_en": "<span>Offers multiple versions of MELD for liver transplant planning.</span>", "short_description_en": "MELD models for liver transplant planning.", "before_use": "<p>MDCalc has recently streamlined the MELD calculator collection.</p>\n<p>On this page, you'll find the original MELD Score (Pre-2016), MELD Na (UNOS/OPTN), and MELD 3.0. MELD Na is the current standard calculation for organ transplantation consideration in the United States.&nbsp; MELD 3.0 better accounts for disparities in organ allotment based on sex.&nbsp;</p>", "instructions_en": "", "slug": "model-end-stage-liver-disease-meld", "logic_language": "javascript", "md5": "8d2d51542c0b5c4739fae626a2420a88", "cmeVersion": null, "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "publishedAt": "2022-08-10T18:48:09.265Z", "vuid": "96b53c6a-1822-41ee-a1f0-3ad8211e9ef5", "versionNumber": 1, "isVisibleInListView": true, "disabled": false, "replacement_calc_id": null, "disabled_reason": null, "search_abbreviation_en": ["Model for End-Stage Liver Disease (MELD)", "Model for End-Stage Liver Disease (Combined MELD)", "combined meld", "meld", "meld 3", "meld 3.0", "end stage liver disease", "liver disease", "end-stage liver disease", "liver disease survival", "transplant", "liver transplant", "MELD Score (Pre-2016)", "MELD original", "MELD Na (UNOS/OPTN)", "MELD Na", "MELD UNOS/OPTN", "unos", "optn"], "seo": {"meta_description_en": "The Model for End-Stage Liver Disease (Combined MELD) offers multiple versions of MELD for liver transplant planning.", "keywords_en": "Model for End-Stage Liver Disease (MELD), meld, meld 3, meld 3.0, end stage liver disease, liver disease, end-stage liver disease, liver disease survival, transplant, liver transplant, Model for End-Stage Liver Disease (Combined MELD), combined meld, MELD Score (Pre-2016), MELD original, MELD Na (UNOS/OPTN), MELD Na, MELD UNOS/OPTN, unos, optn"}, "content": {"reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}, "how_to_use": {"use_case_en": "<ul>\n<li>Determines prognosis and prioritizes receipt of liver transplantation.</li>\n</ul>\n<p><strong>MELD Na (UNOS/OPTN):</strong></p>\n<ul>\n<li>Primarily used to stratify patients &ge;12 years old on liver transplant waiting lists.</li>\n<li>Predicts mortality in the following scenarios: (a) after transjugular intrahepatic portosystemic shunt (TIPS), (b) cirrhotic patients undergoing non-transplantation surgical procedures, (c) acute alcoholic hepatitis, and (d) acute variceal hemorrhage.</li>\n</ul>", "pearls_pitfalls_en": "<ul>\n<li>Values should be no more than 48 hours old.</li>\n<li>MELD can be used on any patient with end stage liver disease irrespective of cirrhosis etiology.</li>\n</ul>\n<p><strong>MELD Na (UNOS/OPTN):</strong></p>\n<ul>\n<li>The MELD Score predicts three-month survival in patients (age 12+) with liver cirrhosis.</li>\n<li>Scores range from 6 to 40, with higher scores correlating with increased severity of liver dysfunction and higher three-month mortality.</li>\n<li>Several conditions are &ldquo;standard MELD exceptions&rdquo; and receive a different score (see <a href=\"#next-steps\">Next Steps &gt; Critical Actions</a>):&nbsp; hepatocellular carcinoma, hepatopulmonary syndrome, portopulmonary hypertension, familial amyloid polyneuropathy, primary hyperoxaluria, cystic fibrosis, hilar cholangiocarcinoma and hepatic artery thrombosis.</li>\n<li>One of the exclusion criteria for the original data set was absence of acute reversible conditions such as spontaneous bacterial peritonitis or prerenal azotemia secondary to dehydration. Therefore, in principle, the score should only be applied after these reversible conditions have been treated, according to the authors (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/17326206\" target=\"_blank\" rel=\"noopener\">Kamath 2007</a>).</li>\n</ul>", "why_use_en": "<ul>\n<li>MELD is the standard used by the Organ Procurement and Transplantation Network (OPTN) and determines who is the highest priority to receive liver transplants in the US.</li>\n<li>It has been widely studied and validated.</li>\n</ul>"}, "next_steps": {"advice_en": "<ul>\n<li>The MELD Score helps to estimate prognosis for patients with end-stage liver disease, and is used to prioritize transplant recipients.</li>\n</ul>\n<p><strong>MELD Na (UNOS/OPTN):</strong></p>\n<ul>\n<li>Consider referral to hepatologist or liver transplant center for patients with MELD Score &ge;10.</li>\n<li>MELD Score should be periodically re-assessed, as it changes with changing lab values.</li>\n<li>All cirrhosis patients should be periodically screened for hepatocellular carcinoma with serum alpha-fetoprotein (AFP) and by appropriate imaging to see if they can earn &ldquo;standard MELD exceptions&rdquo;.</li>\n</ul>", "management_en": "", "critical_actions_en": "<p><strong>MELD Na (UNOS/OPTN): Standard Exceptions</strong></p>\n<ul>\n<li>The following conditions are automatically assigned a MELD Score of 22 (28 in case of hyperoxaluria), with a 10% increase in score every 3 months from diagnosis.</li>\n<li>Hepatocellular carcinoma (HCC) with one lesion between 2-5 cm or two to three lesions &lt;3 cm (Milan criteria), provided no vascular invasion or extrahepatic disease.</li>\n<li>Hepatopulmonary syndrome with PaO2 &lt;60 mmHg on room air.</li>\n<li>Portopulmonary hypertension, with mean pulmonary artery pressure (mPAP) &gt;25 mmHg at rest but maintained &lt;35 mmHg with treatment.</li>\n<li>Hepatic artery thrombosis 7&ndash;14 days post-liver transplantation.</li>\n<li>Familial amyloid polyneuropathy, as diagnosed by identification of the transthyretin (TTR) gene mutation by DNA analysis or mass spectrometry in a biopsy sample and confirmation of amyloid deposition in an involved organ.</li>\n<li>Primary hyperoxaluria with evidence of alanine glyoxylate aminotransferase deficiency (these patients requires combined liver-kidney transplantation).</li>\n<li>Cystic fibrosis with FEV1 (forced expiratory volume in 1 second) &lt;40%.</li>\n<li>Hilar cholangiocarcinoma.</li>\n</ul>"}, "about": {"formula_en": "<p><strong>MELD (Original, Pre-2016)&nbsp;</strong>= (0.957*ln(Serum creatinine) + 0.378*ln(Serum bilirubin) + 1.120*ln(INR) + 0.643)*10</p>\n<p>(if hemodialysis, value for Creatinine is automatically set to 4.0)</p>\n<p>Note: If any score is &lt;1, the MELD assumes the score is equal to 1.</p>\n<p>&nbsp;</p>\n<p><strong>MELD Na (UNOS/OPTN):</strong></p>\n<p>Per OPTN policy, January 2016 (pages 4&ndash;5):</p>\n<p>Candidates who are at least 12 years old receive an initial MELD(i) score equal to:</p>\n<p>MELD(i) = 0.957*ln(Creatinine) + 0.378*ln(Bilirubin) + 1.120*ln(INR) + 0.643</p>\n<p>Then, round to the tenth decimal place and multiply by 10.&nbsp;</p>\n<p>If MELD(i) &gt; 11, perform additional MELD calculation as follows:</p>\n<p>MELD = MELD(i) + 1.32*(137 &ndash; Na) &ndash;&nbsp; [0.033*MELD(i)*(137 &ndash; Na)]</p>\n<p>&nbsp;</p>\n<p><strong>MELD 3.0&nbsp;</strong>= 1.33*(Female) + 4.56*ln(Serum bilirubin) + 0.82*(137 - Sodium) &ndash; 0.24*(137 - Sodium)*ln(Serum bilirubin) + 9.09*ln(INR) + 11.14*ln(Serum creatinine) + 1.85*(3.5 &ndash; Serum albumin) &ndash; 1.83*(3.5 &ndash; Serum albumin)*ln(Serum creatinine) + 6,</p>\n<p>rounded to the nearest integer</p>\n<ul>\n<li>Serum bilirubin, INR, and serum creatinine values below 1.0 are set to 1.0.</li>\n<li>Sodium is limited to a range of 125-137 mEq/L, and if outside of these bounds, is set to the nearest limit.</li>\n<li>Serum albumin is limited to a range of 1.5-3.5 g/dL, and if outside of these bounds, is set to the nearest limit.</li>\n<li>Maximum serum creatinine is 3.0 mg/dL, and if above this bound, is set to 3.0 mg/dL.</li>\n</ul>", "more_info_en": "<p>Interpretation:</p>\n<p><strong>MELD (Original, Pre-2016) and MELD Na (UNOS/OPTN)</strong></p>\n<table style=\"width: 76.4151%;\">\n<tbody>\n<tr>\n<td style=\"width: 52.8796%;\">\n<p><strong>MELD Score</strong></p>\n</td>\n<td style=\"width: 47.1204%;\">\n<p><strong>Mortality</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 52.8796%;\">\n<p>&le;9</p>\n</td>\n<td style=\"width: 47.1204%;\">\n<p>1.9%</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 52.8796%;\">\n<p>10&ndash;19</p>\n</td>\n<td style=\"width: 47.1204%;\">\n<p>6.0%</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 52.8796%;\">\n<p>20&ndash;29</p>\n</td>\n<td style=\"width: 47.1204%;\">\n<p>19.6%</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 52.8796%;\">\n<p>30&ndash;39</p>\n</td>\n<td style=\"width: 47.1204%;\">\n<p>52.6%</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 52.8796%;\">\n<p>&ge;40</p>\n</td>\n<td style=\"width: 47.1204%;\">\n<p>71.3%</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>More Info:&nbsp;<a href=\"https://optn.transplant.hrsa.gov/media/1575/policynotice_20151101.pdf\" target=\"_blank\" rel=\"noopener\">OPTN/UNOS Documentation on MELD and PELD</a>&nbsp;</p>\n<p>&nbsp;</p>\n<p><strong>MELD 3.0</strong></p>\n<p>Estimated 90-day survival = 0.946<sup>exp(0.17698*MELD 3.0 &ndash; 3.56)</sup> * 100</p>", "evidence_based_medicine_en": "", "references_list": {"Validation": [{"text": "Wiesner R, United Network for Organ Sharing Liver Disease Severity Score Committee, et al. Model for end-stage liver disease (MELD) and allocation of donor livers.Gastroenterology. 2003 Jan;124(1):91-6.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/12512033"}], "Outcomes": [], "Validations": [], "Original/Primary Reference": [{"text": "Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/11172350"}, {"text": "Kim WR, Mannalithara A, Heimbach JK, et al. Meld 3. 0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887-1895.e4.", "href": "https://pubmed.ncbi.nlm.nih.gov/34481845/"}], "Other References": [{"text": "Kremers WK, van IJperen M, Kim WR, Freeman RB, Harper AM, Kamath PS, Wiesner RH. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients.Hepatology. 2004 Mar;39(3):764-9.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/14999695"}, {"text": "Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007 Mar;45(3):797-805.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/17326206"}, {"text": "OPTN 2016 MELD Policy Changes", "href": "https://optn.transplant.hrsa.gov/news/meld-serum-sodium-policy-changes/"}, {"text": "Freeman RB Jr, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, Klintmalm G, Blazek J, Hunter R, Punch J. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.Liver Transpl. 2006;12(12 Suppl 3):S128.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/17123284"}, {"text": "Trivedi HD. The evolution of the meld score and its implications in liver transplant allocation: a beginner\u2019s guide for trainees. ACG Case Rep J. 2022;9(5):e00763.", "href": "https://pubmed.ncbi.nlm.nih.gov/35919673/"}], "Clinical Practice Guidelines": [], "Manufacturer Website": []}}, "creator": [{"qa_en": null, "approved": null, "name": "Dr. Patrick S. Kamath", "creator_info": {"deceased": null, "about_en": "<p>Patrick S. Kamath, MD, is a professor of gastroenterology and hepatology at the Mayo Clinic in Rochester, Minnesota. His research interests include acute-on-chronic liver failure, nonalcoholic fatty liver disease, polycystic liver disease, Budd-Chiari syndrome and hereditary hemorrhagic telangiectasia. Dr. Kamath is internationally renowned as a leading researcher in hepatology and has also won numerous awards as an educator.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-patrick-s-kamath.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Kamath%20PS%5BAuthor%5D"}}, {"qa_en": null, "approved": null, "name": "Dr. W. Ray Kim", "creator_info": {"deceased": null, "about_en": "<p>W. Ray Kim, MD, is the Chief of the Division of Gastroenterology &amp; Hepatology at Stanford University. He formerly studied in Seoul, South Korea, and completed fellowships in gastroenterology and hepatology at the Mayo Clinic.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-w-ray-kim.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Kim+WR%5BAuthor%5D"}}], "contributor": {"expert_name": []}}, "input_schema": [{"type": "radio", "name": "equation", "default": null, "show_points": false, "optional": false, "conditionality": null, "tips_en": "", "label_en": "<p>Equation</p>", "option_fhir_rules": null, "options": [{"label": "MELD Score (Original, Pre-2016)", "value": 0}, {"label": "MELD Na (UNOS/OPTN)", "value": 1}, {"label": "MELD 3.0", "value": 2}], "mdcalc_info_concept": null}, {"type": "radio", "name": "dialysis", "default": null, "show_points": false, "optional": false, "conditionality": "equation == 0 || equation == 1", "tips_en": "", "label_en": "<p>Dialysis at least twice in the past week</p>", "option_fhir_rules": null, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "mdcalc_info_concept": null}, {"type": "radio", "name": "sex", "default": null, "show_points": false, "optional": false, "conditionality": "equation == 2", "tips_en": "", "label_en": "<p>Sex</p>", "option_fhir_rules": null, "options": [{"label": "Male", "value": 0}, {"label": "Female", "value": 1}], "mdcalc_info_concept": null}, {"conditionality": "equation == 0 || equation == 1 || equation == 2", "tips_en": "", "optional": false, "name": "creatinine", "type": "textbox", "label_en": "<p>Creatinine</p>", "default": null, "inct": null, "unit": "cr", "fhir_rules": null, "unit_info": {"name": "Creatinine", "conversion": 88.4, "error_min": 0.01, "error_max": 40, "warn_min": 0, "warn_max": 10, "normal_max_si": 115, "normal_min_si": 62, "normal_min_us": 0.7, "units_si": "\u00b5mol/L", "units_us": "mg/dL", "normal_max_us": 1.3}}, {"conditionality": "equation == 0 || equation == 1 || equation == 2", "tips_en": "", "optional": false, "name": "bilirubin", "type": "textbox", "label_en": "<p>Bilirubin</p>", "default": null, "inct": null, "unit": "bili", "fhir_rules": null, "unit_info": {"name": "Bilirubin", "conversion": 17.104, "error_min": 1e-08, "error_max": 50, "warn_min": 0, "warn_max": 20, "normal_max_si": 32.49, "normal_min_si": 5.13, "normal_min_us": 0.3, "units_si": "\u00b5mol/L", "units_us": "mg/dL", "normal_max_us": 1.9}}, {"conditionality": "equation == 0 || equation == 1 || equation == 2", "tips_en": "", "optional": false, "name": "inr", "type": "textbox", "label_en": "<p>INR</p>", "default": null, "inct": null, "unit": "inr", "fhir_rules": null, "unit_info": {"name": "INR", "conversion": 1, "error_min": 0.1, "error_max": 20, "warn_min": 0.5, "warn_max": 10, "normal_max_si": 1.2, "normal_min_si": 0.8, "normal_min_us": 0.8, "units_si": " ", "units_us": " ", "normal_max_us": 1.2}}, {"conditionality": "equation == 1 || equation == 2", "tips_en": "", "optional": false, "name": "sodium", "type": "textbox", "label_en": "<p>Sodium</p>", "default": null, "inct": null, "unit": "na", "fhir_rules": null, "unit_info": {"name": "Sodium", "conversion": 1, "error_min": 100, "error_max": 200, "warn_min": 0, "warn_max": 170, "normal_max_si": 145, "normal_min_si": 136, "normal_min_us": 136, "units_si": "mmol/L", "units_us": "mEq/L", "normal_max_us": 145}}, {"conditionality": "equation == 2", "tips_en": "", "optional": false, "name": "albumin", "type": "textbox", "label_en": "<p>Albumin</p>", "default": null, "inct": null, "unit": "alb", "fhir_rules": null, "unit_info": {"name": "Albumin", "conversion": 10, "error_min": 0, "error_max": 7, "warn_min": 1, "warn_max": 6, "normal_max_si": 55, "normal_min_si": 35, "normal_min_us": 3.5, "units_si": "g/L", "units_us": "g/dL", "normal_max_us": 5.5}}], "chief_complaint_en": ["Abdominal Pain", "Fatigue", "Jaundice", "Loss of Appetite", "Nausea", "Swelling", "Vomiting"], "specialty_en": ["Emergency Medicine", "Gastroenterology", "Hepatology"], "purpose_en": ["Prognosis"], "system_en": ["Gastrointestinal", "Hepatic"], "disease_en": ["Chronic Liver Disease", "Cirrhosis", "Hepatitis"], "tags": [], "versions": [], "related_calcs": [{"calcId": 10147, "short_title_en": "UKELD Score", "slug": "united-kingdom-model-end-stage-liver-disease-ukeld"}, {"calcId": 10240, "short_title_en": "CLIF-C ACLF", "slug": "clif-c-aclf-acute-chronic-liver-failure"}, {"calcId": 10393, "short_title_en": "GI-GPA", "slug": "graded-prognostic-assessment-for-gastrointestinal-cancer-gigpa"}]}